Lipids in Health and Disease (Dec 2010)

Simvastatin impairs murine melanoma growth

  • Barros Francisco E,
  • Borelli Primavera,
  • Bohatch Milton S,
  • Oliveira Karen A,
  • F Otuki Michel,
  • Favero Giovani M,
  • Maria Durvanei A,
  • Fernandes Daniel,
  • Bydlowski Sergio P

DOI
https://doi.org/10.1186/1476-511X-9-142
Journal volume & issue
Vol. 9, no. 1
p. 142

Abstract

Read online

Abstract Background Statins induces cell cycle arrest, apoptosis, reduction of angiogenic factors, inhibition of the endothelial growth factor, impairing tissue adhesion and attenuation of the resistance mechanisms. The aim of this study was evaluate the anti-tumoral activity of simvastatin in a B16F10 melanoma-mouse model. Methods Melanoma cells were treated with different concentrations of simvastatin and assessed by viability methods. Melanoma cells (5 × 104) were implanted in two month old C57Bl6/J mice. Around 7 days after cells injection, the oral treatments were started with simvastatin (5 mg/kg/day, p.o.). Tumor size, hematological and biochemical analyses were evaluated. Results Simvastatin at a concentration of 0.8 μM, 1.2 μM and 1.6 μM had toxic effect. Concentration of 1.6 μM induced a massive death in the first 24 h of incubation. Simvastatin at 0.8 μM induces early cell cycle arrest in G0/G1, followed by increase of hypodiploidy. Tumor size were evaluated and the difference of treated group and control, after ten days, demonstrates that simvastatin inhibited the tumor expansion in 68%. Conclusion Simvastatin at 1.6 μM, presented cytototoxicity after 72 h of treatment, with an intense death. In vivo, simvastatin being potentially useful as an antiproliferative drug, with an impairment of growth after ten days.